Abstract 230P
Background
Prostate cancer(Pca) is one of the most common types of cancer in men. Androgen deprivation therapy(ADT) is the main choice of Pca treatment. However, major investigations have focussed on caucasians population. Here, we intended to explore the molecular characteristics and clinical characteristics between localized and metastatic of Chinese Pca patients.
Methods
29 Pca patients with localized or metastatic tumor were enrolled. Somatic and germline mutations were identified via targeted next generation sequencing with Acornmed panel including 808 genes associated with tumor development. Sequencing data were analyzed to call tumor specific single nucleotide variants (SNV), small insertions and deletions (InDels), copy number alterations (CNA) and chromosomal rearrangements. Clinical data of the cohort was collected and analyzed.
Results
Median age was 68 yrs (range 53-80), 62% were classified as metastatic(M), and 17% had received one prior ADT drug. The most common somatic mutations were observed in TP53(24%), FOXA1(21%), CDK12(17%), AR(10%), KRAS(7%), PIK3CA(7%), SPOP(7%), PTCH1(7%), ATM(7%) and TSC2(3%) genes. Median tumor mutational burden (TMB) was 7 Mus/ Mb(1-22). Germline pathogenic or likely pathogenic mutations occurred 17% of Pca patients, 4/5 mutations were DNA damage response genes, and 4 patients had metastatic Pca. AR was shared by both localized and metastatic Pca (2 in ADT- and 1 in ADT+). Mutated CDK12 was only detected in patients without any history of ADT drug(3 in M- and 2 in M+). Interestingly, Tp53 mutations were only detected in metastatic Pca(7/18 M+). FOXA1 mutations were observed more frequently in patients with localized Pca(4/11M- versus 2/18 M+).
Conclusions
These findings show differences in the genomics alterations of metastatic and localized prostate cancer. Germline mutations are more likely to be detected in patients with advanced prostate cancer. Mutations in the TP53 gene are more common in advanced prostate cancer. Additional correlative analyses are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yang, H. Wang, F. Lou, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd., All other authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session